BioPharma Clinical Trials

Thermo Fisher Scientific Launches CorEvitas Adolescent Alopecia Areata Registry to Advance Real-World Research

Thermo Fisher Scientific Inc., the world leader in serving science, announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Reg...

 February 06, 2025 | News

Harbour BioMed Secures NMPA Approval for HBM9378/SKB378 and Signs $970M Global Licensing Deal

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel anti...

 February 06, 2025 | News

WHO Grants ‘Emestedastat’ as the Official INN for Actinogen’s Xanamem®, a First-in-Class Cortisol Regulator

Actinogen Medical Limited (ASX: ACW) has announced that the World Health Organization (WHO) has granted the nonproprietary name ‘emestedastat...

 February 06, 2025 | News

Argent BioPharma’s CannEpil® Offers New Hope for Drug-Resistant Epilepsy Patients

Argent BioPharma Limited (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company, is pioneering a transformative approach to drug-resistant e...

 February 06, 2025 | News

Akeso Completes Global Phase III Enrollment for Ivonescimab in Squamous NSCLC

Akeso, Inc. is excited to announce the completion of patient enrollment in the global Phase III clinical trial (HARMONi-6/AK112-306) evaluating ivonescimab...

 February 06, 2025 | News

Nuvation Bio Launches Expanded Access Program in the U.S. for Taletrectinib in ROS1+ NSCLC

Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology,  announced it has initiated ...

 February 04, 2025 | News

Bristol Myers Squibb’s Breyanzi Recommended for EU Approval After 97% Response Rate in Follicular Lymphoma

Recommendation based on the Phase 2 TRANSCEND FL study in which 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving comple...

 February 03, 2025 | News

China Approves Sarclisa as First Anti-CD38 Therapy for Newly Diagnosed Multiple Myeloma Patients

  Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant  A...

 January 31, 2025 | News

Kazia Therapeutics Launches Clinical Trial for Paxalisib-Immunotherapy Combination in Advanced Breast Cancer

Kazia Therapeutics Limited an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial eval...

 January 31, 2025 | News

Cognizant and Medidata Expand AI-Driven Partnership to Advance Clinical Trials

The organizations plan to support clients through expanded partnership and offer broader access to Medidata's AI-powered technologies to accelerate clinica...

 January 31, 2025 | News

Clarity Pharmaceuticals Secures Second FDA Fast Track Designation for 64Cu-SAR-bisPSMA in Prostate Cancer Imaging

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation product...

 January 27, 2025 | News

Akeso Secures CDE Approval for IL-17 Monoclonal Antibody Gumokimab to Address Plaque Psoriasis

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting mon...

 January 27, 2025 | News

Kelun-Biotech Secures NMPA Approval for Tagitanlimab in First-Line Treatment of Nasopharyngeal Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from Natio...

 January 24, 2025 | News

Allurion Technologies to Initiate Clinical Study Combining Allurion Program with GLP-1 Therapy to Transform Obesity Care

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its ...

 January 24, 2025 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close